Competitor Analysis: Interferon
Product description
The Competitive Intelligence Report Interferon as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant and natural interferon alpha, beta, gamma, lambda and of other subtypes for treatment of hepatitis B and C, other infectious diseases, cancer and multiple sclerosis, respectively. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report provides information on the marketed interferon preparations and includes a compilation of current active projects in research and development of novel interferon products including novel presentation or delivery formats. In addition, the report lists company-specific product portfolios and R&D pipelines of interferon products and projects. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The Competitive Intelligence Report Interferon as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant and natural interferon alpha, beta, gamma, lambda and of other subtypes for treatment of hepatitis B and C, other infectious diseases, cancer and multiple sclerosis, respectively. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report provides information on the marketed interferon preparations and includes a compilation of current active projects in research and development of novel interferon products including novel presentation or delivery formats. In addition, the report lists company-specific product portfolios and R&D pipelines of interferon products and projects. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1. INTERFERON ALPHA, BETA AND OTHER SUB-TYPES
a) INTERFERON alpha
Interferon alpha sales 2012 of branded products in regulated markets
1st generation Interferon alpha-2a in regulated markets
1st generation Interferon alpha-2a in non-regulated markets
Next generation Interferon alpha-2a in regulated markets
Next generation Interferon alpha-2a in non-regulated markets and biosimilars
1st generation Interferon alpha-2b in regulated markets
1st generation Interferon alpha-2b in non-regulated markets and biosimilars
Next generation Interferon alpha-2b in regulated markets
Next generation Interferon alpha-2b in non-regulated markets and biosimilars
Other Interferon alpha sub-types
Interferon alpha with not specified sub-type – 1/2
Purified natural human interferon alpha
b) Consensus INTERFERONs
c) INTERFERON beta
Interferon beta sales 2012 of branded products in regulated markets
1st generation Interferon beta-1a in regulated markets
1st generation Interferon beta-1a in non-regulated markets and biosimilars
1st generation Interferon beta-1b in regulated markets
1st generation Interferon beta-1b in non-regulated markets and biosimilars
1st generation Interferon beta with not disclosed sub-type
Next generation Interferon beta in regulated markets
Purified natural human interferon beta
d) INTERFERON gamma
e) Other INTERFERONs
2. CORPORATE INTERFERON PRODUCT PORTFOLIOS AND R&D PIPELINES
a) INTERFERON alpha
Interferon alpha sales 2012 of branded products in regulated markets
1st generation Interferon alpha-2a in regulated markets
1st generation Interferon alpha-2a in non-regulated markets
Next generation Interferon alpha-2a in regulated markets
Next generation Interferon alpha-2a in non-regulated markets and biosimilars
1st generation Interferon alpha-2b in regulated markets
1st generation Interferon alpha-2b in non-regulated markets and biosimilars
Next generation Interferon alpha-2b in regulated markets
Next generation Interferon alpha-2b in non-regulated markets and biosimilars
Other Interferon alpha sub-types
Interferon alpha with not specified sub-type – 1/2
Purified natural human interferon alpha
b) Consensus INTERFERONs
c) INTERFERON beta
Interferon beta sales 2012 of branded products in regulated markets
1st generation Interferon beta-1a in regulated markets
1st generation Interferon beta-1a in non-regulated markets and biosimilars
1st generation Interferon beta-1b in regulated markets
1st generation Interferon beta-1b in non-regulated markets and biosimilars
1st generation Interferon beta with not disclosed sub-type
Next generation Interferon beta in regulated markets
Purified natural human interferon beta
d) INTERFERON gamma
e) Other INTERFERONs
2. CORPORATE INTERFERON PRODUCT PORTFOLIOS AND R&D PIPELINES